Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer

Kragelj, Borut; Zaletel-Kragelj, Lijana; Sedmak, Boris; Čufer, Tanja; Červek, Jožica

doi:10.1016/j.radonc.2005.01.007

Cited by 37 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further trials studying radiation therapy with various radiosensitizing agents have been performed since. These studies have investigated single-agents (cisplatin [22] , gemcitabine [23] , vinblastine [24] , amifostine [25] , liposomal doxorubicin [26] ) and combinations (cisplatin-paclitaxel [27] , cisplatin-5FU [28] , carbogen-nicotinamide [29] ).…”

Section: Localized Muscle-invasive Diseasementioning

confidence: 99%

Systemic therapy for bladder cancer – a medical oncologist’s perspective

Teply¹,

Kim²

2014

JST

View full text Add to dashboard Cite

Advanced bladder cancer, both muscle-invasive localized disease and metastatic disease, is managed with systemic chemotherapy. Cisplatin-based multi-agent chemotherapy remains the cornerstone for systemic therapy. MVAC (methotrexate-vinblastine-doxorubicin-cisplatin) has been most rigorously studied, both neoadjuvantly and for palliation of metastatic disease. For metastatic disease, cisplatin-gemcitabine (GC) has compared favorably to MVAC due to improved tolerability with similar efficacy. GC has been adopted as standard therapy. Neoadjuvant chemotherapy for muscle-invasive bladder cancer improves survival among those patients eligible to receive cisplatin. Adjuvant chemotherapy is difficult to administer effectively given morbidity of radical cystectomy, and studies have shown mixed results about its benefit. Non-cisplatin regimens have been investigated but remain experimental and reserved for those not candidates for cisplatin in the metastatic setting. While multiple agents have been studied after metastatic disease progression after cisplatin-based therapy, there remain no FDA-approved therapies for the second line. Future trials with anti-VEGF therapy and immunotherapy are actively being investigated. This review examines the systemic therapy available to oncologists with current evidence and future directions.

show abstract

Section: Localized Muscle-invasive Diseasementioning

confidence: 99%

Systemic therapy for bladder cancer – a medical oncologist’s perspective

Teply¹,

Kim²

2014

JST

View full text Add to dashboard Cite

show abstract

“…Several prospective and retrospective studies have investigated the efficacy of neoadjuvant chemotherapy in the setting of TMT. RTOG 89-03 represents the first large randomized trial directly comparing a standard TMT protocol with and without neoadjuvant cisplatin, methotrexate, and vinblastine (CMV) [61]. This study was terminated early due to high rates of severe toxicities, with only 64% of included patients completing their specified treatment regimen.…”

Section: The Role Of Neoadjuvant Chemotherapy Prior To Turbt In Tmtmentioning

confidence: 99%

The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer

Russell

Lebastchi

Borza

et al. 2016

BLC

View full text Add to dashboard Cite

While radical cystectomy (RC) with pelvic lymph node dissection (PLND) represents the accepted gold standard for the treatment of muscle-invasive bladder cancer, this treatment approach is associated with significant morbidity. As such, bladder preservation strategies are often utilized in patients who are either deemed medically unfit due to significant comorbidities or whom decline management with RC and PLND secondary to its associated morbidity. In a select group of patients, meeting strict criteria, bladder preservation approaches may be employed with curative intent. Trimodal therapy, consisting of complete transurethral resection of bladder tumor (TURBT), chemotherapy, and radiation therapy has demonstrated durable oncologic control and long-term survival in a number of studies. The review presented here provides a description of trimodal therapy and the role of TURBT in bladder preservation for patients with muscle-invasive bladder cancer.

show abstract

“…As radiotherapy alone has not been shown to be superior to other conservative treatments [168], several studies have investigated the role of combined radiotherapy with chemotherapy to improve the benefit for patients [169][170][171][172] and suggested higher response rates and improved survival. Current approaches also concentrate on improved strategies in combination with hyperthermia [173] or inhibition of oncogene products such as HER2/neu in combination with RCT using paclitaxel and trastuzumab [174].…”

Section: Radiochemotherapymentioning

confidence: 99%

Strategies to improve drug delivery in bladder cancer therapy

Wirth

Plattner

Gabor

2009

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Bladder cancer is the ninth most common malignancy in the world featuring very high gender variability in occurrence. Current options for bladder cancer therapy include surgery, immunotherapy, chemotherapy and radiotherapy with a trend towards multimodal treatments. However, successful management remains a challenge for urologists and oncologists because of the high risk for recurrence and progression. Particularly in the field of bladder cancer chemotherapy, efficacy of treatment might be improved by advanced drug delivery strategies aimed at prolonged residence time within the bladder cavity and increased permeability of the bladder wall during intravesical instillation. Moreover, a deeper understanding of the biology of bladder carcinogenesis and malignant progression stimulated the development of a new generation of anticancer drugs for targeted therapies that might result in increased treatment specificity together with lower toxic potential and higher therapeutic indices. This review discusses the available strategies for 'targeted therapy', focusing on molecular targets, and for 'controlled delivery', comprising all other approaches towards improved drug delivery.

show abstract

Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer

Cited by 37 publications

References 16 publications

Systemic therapy for bladder cancer – a medical oncologist’s perspective

Systemic therapy for bladder cancer – a medical oncologist’s perspective

The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer

Strategies to improve drug delivery in bladder cancer therapy

Contact Info

Product

Resources

About